Effect of Atorvastatin on the Disease Activity and Severity of Rheumatoid Arthritis: Double-Blind Randomized Controlled Trial

HMG-CoA (3-hydroxy-3- methylglutary lcoenzyme A) reductase inhibitors (statins) have anti-inflammatory properties which may be particularly useful in rheumatoid arthritis to suppress disease activity and inflammatory factors. The purpose of this clinical trial was to determine anti-inflammatory prop...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and diagnostic research 2016-05, Vol.10 (5), p.OC32-OC36
Main Authors: Mowla, Karim, Rajai, Elham, Ghorbani, Ali, Dargahi-Malamir, Mehrdad, Bahadoram, Mohammad, Mohammadi, Shooka
Format: Article
Language:English
Subjects:
anti-inflammatory agents
erythrocyte sedimentation rate
hmg-coa
swollen joint count
tender joint count
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HMG-CoA (3-hydroxy-3- methylglutary lcoenzyme A) reductase inhibitors (statins) have anti-inflammatory properties which may be particularly useful in rheumatoid arthritis to suppress disease activity and inflammatory factors. The purpose of this clinical trial was to determine anti-inflammatory properties of statins in rheumatoid arthritis. Eighty Iranian patients with rheumatoid arthritis, aged between 19 to 75 years were recruited to take part in this randomized, double-blind placebo-controlled trial. Subjects were randomly allocated to two groups to take atorvastatin or placebo 40 mg daily as an adjunct to current disease-modifying anti-rheumatic drugs (DMARDs) treatment. Disease Activity Score-28 (DAS28), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), swollen joint count (SJC) & tender joint count (TJC) were assessed before and after three months intervention. Analysis was based on intention to treat. DAS28 significantly declined in the atorvastatin group in comparison with placebo (p< 0.001). SJC, TJC, CRP and ESR also were significantly dropped in the atorvastatin group in comparison with placebo. It can be concluded that atorvastatin can suppress RA activity and inflmmatory factors in RA patients for high to moderate grade of inflmmation.
ISSN:2249-782X
0973-709X
DOI:10.7860/JCDR/2016/16538.7814